NASDAQ:RIGL 5 November 2025 - 17 June 2026

Rigel’s stock has been on a tear in 2025, reflecting its improving fundamentals. As of November 5, 2025, RIGL trades around $38/share, up over 30% in a single day after its blowout Q3 earnings reportstockanalysis.com. The post-earnings volatility has been extreme – initially, shares fell ~7–8% in after-hours trading on Nov. 4 despite the strong results, possibly due to profit-taking or tempered forward outlook, dipping to about $30.32investing.com. However, sentiment swiftly reversed: by the next trading session, buyers piled in, and Rigel stock skyrocketed to new multi-month highs. The stock is now only a few points shy of its 52-week peak of $43.72investing.com. Even before this week’s jump, Rigel had been a big winner in 2025. Year-to-date the stock had already gained roughly 82% through early Novembernasdaq.com, massively outperforming the S&P 500nasdaq.com. Rigel was recently highlighted by CNBC as one of the top-performing Bay Area biotech stocks, with shares up ~50% over the past three months alonestocktradersmarket.com. The rally has been fueled by the company’s rapid revenue growth and newfound profitability. “We have a business that’s growing substantially,” CEO Raul Rodriguez noted in a recent CNBC interviewstocktradersmarket.com. He pointed out that Rigel’s revenues grew ~30% annually on average over the